ABSTRACT

We performed a prospective, multicenter study to assess the tolerance and possible short-term effects of allergen vaccines administered according to a cluster schedule in the months immediately preceding the onset of the pollen season.

The study was carried out in eight centers and included 191 patients (children and adults) with allergic respiratory disease due to sensitization to olive tree and/or grass pollen. Of these, 34 patients acted as controls and the remaining patients received immunotherapy administered in the initiation phase according to a cluster schedule of eight doses injected on four visits. After 3 months of treatment, significant differences were found between the two groups in medication consumption (antihistamines in drops and oral formulations: \( p = 0.045 \) and \( p = 0.001 \), respectively; short-acting \( \beta_2 \)-agonist treatments: \( p = 0.004 \) and respiratory symptoms (wheezing and coughing: \( p = 0.035 \) and 0.014, respectively). The cytokine profile (interleukin [IL]-4, 5, 10 and 2, interferon [IFN-\( \gamma \)], and tumor necrosis factor [TNF-\( \alpha \)]) was determined before the start of treatment and at the end of follow-up (4-5 months). Levels of IL-4, 5 and 10 (Th2 profile) decreased while those of IL-2, IFN-\( \gamma \), and TNF-\( \alpha \) (Th1 profile) decreased. These differences were more marked in the active group than in the control group but were not statistically significant. No severe adverse effects were recorded. This study shows that the schedule tested had an acceptable tolerance profile and produced significant changes in symptom and medication scores after a few months of treatment. A double-blind, placebo-controlled study is needed to confirm these results.


RESUMEN

Se ha llevado a cabo un estudio prospectivo y multicéntrico con el objetivo de valorar la tolerancia y posible efecto a corto plazo de las vacunas alérgicas administradas bajo pauta cluster en los meses inmediatamente anteriores al inicio de la estación polínica. El estudio se realizó en 8 centros, incluyéndose un total de 191 pacientes (niños y adultos) con enfermedad alérgica respiratoria por sensibilización a polen de olivo y/o gramíneas. De ellos, 34 actuaron como control y los restantes recibieron tratamiento inmunológico administrado en la fase de inicio según un esquema cluster de ocho dosis inyectadas en cuatro visitas. Tras 3 meses de tratamiento, se observaron significativas diferencias entre los dos grupos en el consumo de medicación (antihistamínicos en forma de gotas y formulaciones orales: \( p = 0.045 \) y \( p = 0.001 \), respectivamente; tratamientos \( \beta_2 \)-agonistas: \( p = 0.004 \) y síntomas respiratorios (sibilancias y tos: \( p = 0.035 \) y 0.014, respectivamente). El perfil de citocinas (interleucina [IL]-4, 5, 10 y 2, interferón [IFN-\( \gamma \)], y factor de necrosis tumoral [TNF-\( \alpha \)]) fue determinado antes de iniciar el tratamiento y al finalizar la observación (4-5 meses). Los niveles de IL-4, 5 y 10 (perfil Th2) disminuyeron mientras que los de IL-2, IFN-\( \gamma \) y TNF-\( \alpha \) (perfil Th1) disminuyeron. Estas diferencias fueron más marcadas en el grupo activo que en el control pero no fueron estadísticamente significativas. No se registraron efectos adversos graves. Este estudio muestra que el esquema probado presentó un perfil de tolerancia aceptable y produjo cambios significativos en los síntomas y en la medicación después de unos pocos meses de tratamiento. Se necesita un estudio doble ciego, placebo controlado para confirmar estos resultados.


Correspondence: F. de la Torre
ALK-Abelló, SA
C/ Miguel Fleta, 19
28037 Madrid
E-mail:fernando.delatorre@es.alk-abello.com
tolero y a los pacientes restantes se les administró inmunoterapia bajo una pauta cluster, en la fase de iniciación, de 8 dosis administradas en 4 visitas.

Tras 3 meses de tratamiento, se registraron diferencias significativas entre ambos grupos en el consumo de medicación (antihistamínicos en colirio y orales –p = 0,045 y p = 0,001 respectivamente– y β2 de corta duración –p = 0,004–) así como en síntomas y mejorando la tolerancia, con p = 0,035 y 0,014 respectivamente–). Por otro lado, se determinó el perfil de citocinas (IL-4, 5, 10 y 2, IFN-γ) de forma previa al inicio del tratamiento y al finalizar el seguimiento (4-5 meses). Se observaron descensos en los niveles de IL-4, 5 y 10 (perfil TH2) y aumento en los niveles de IL-2, IFN-γ y TNF-α (perfil TH1), más marcados en el grupo activo que en el control, sin alcanzar significación estadística. No se registraron efectos adversos severos.

Por tanto, podemos observar que la pauta ensayada mostró un adecuado perfil de tolerancia, y tras pocos meses de tratamiento se registraron cambios significativos en la puntuación de síntomas y medicación, siendo necesaria la realización de un estudio con un diseño doble ciego frente a placebo para confirmar los resultados obtenidos.


**INTRODUCTION**

The search for a new subcutaneous immunotherapy administration schedule of the cluster or grouped type entails the consideration of various factors. In first place, it is necessary to have allergen extracts in which major allergens are correctly identified and quantified in micrograms/milliliter and minor allergens are identified. Of the standardization methods that are currently available, this is the one that best guarantees batch-to-batch equivalence between allergen extracts. In second place, the schedule must significantly reduce the number of doses and visits needed to reach the maintenance dose, compared to conventional schedules. This should reduce the cost of administering such treatments for both patients and the institutions where treatment is given, in addition to improving compliance with treatment. In third place, the schedule must be sufficiently flexible to allow dose adjustments, as needed, for factors such as the appearance of adverse reactions or an increase in allergen pressure.

Different multicenter studies have been carried out that take all these factors into consideration, resulting in the development of a cluster schedule of extracts quantified in Mass Units of mites and pollen (olive and/or grasses), as well as the development of a conventional regimen with an important reduction in the number of doses required compared to the 12 doses traditionally recommended. The tolerance demonstrated from the beginning was good. Nevertheless, the number of systemic reactions to pollens in a specific cluster suggested that the regimen should be modified to improve results. Once the above studies finalized, a second question emerged: Can a short-term clinical benefit be obtained with a cluster schedule administered in the months just before the pollen season?

In order to find a schedule that would reduce the percentage of adverse reactions and test a first approach that could produce a short-term benefit to patients, the present observational, open, prospective, multicenter, controlled study was designed.

**MATERIAL AND METHODS**

**Patients**

A total of 191 patients (ages 7 to 50 years) were included in 8 clinical groups. The inclusion criteria were: clinical history of seasonal allergic rhinitis or rhinoconjunctivitis with or without asthma symptoms due to sensitization to *Olea europaea* and/or a mixture of grasses (*Dactylis*, *Festuca*, *Lolium*, *Phleum*, and *Poat*) of at least 1 year duration, with positive skin tests and/or specific IgE in serum (≥ class 2, CAP Pharmacia, Uppsal, Sweden). Patients who had received previous immunotherapy, were sensitized to other clinically relevant allergens, could not receive the treatment under the supervision of an allergy specialist, or had a contraindication for the administration of immunotherapy according to WHO criteria were excluded from the study. Of 191 patients, 34 acted as controls (these patients that met the same inclusion criteria, but were seen so close to pollen season that it was impossible to initiate immunotherapy). Therefore, they received only the symptomatic medication required for adequate control of their allergy symptoms.

**Immunotherapy**

Immunotherapy was administered subcutaneously using an extract of *Olea europaea* and/or a mixture of 5 grasses (Pangrarin® Depot-UM, ALK-ABELLÓ,
S.A., Madrid, Spain). In both cases, aluminum hydroxide gel-adsorbed allergen extracts were used. Extracts were biologically standardized with the major allergens (Ole e1 and Group 5 respectively) quantified in Mass Units, according to the methodology described by the manufacturer. The dosing schedule used is shown in Table I. All doses were administered under the supervision of an allergist at each participating center. The clinical situation of each patient before each dose was evaluated following the instructions described in the Position Paper of the EAACI. No patient received premedication with antihistamines before any dose.

**Safety monitoring**

Adverse reactions were recorded according to the classification cited in the Position Paper of the EAACI.

**Assessment of clinical efficacy**

Clinical efficacy was assessed using diary cards to record symptoms and medication consumption during the pollen season. Symptoms were scored as follows: 0 (none), 1 (mild), 2 (moderate), and 3 (severe). In the case of medication consumption, the use of short-acting antihistamines (drops, oral, or parenteral formulations) and β2-agonists was recorded: 1 point/dose. Inhaled corticosteroids (nasal/bronchial): 2 points. Oral or parenteral corticoids: 3 points.

**Modification of parameters in vitro**

IL-2, IL-4, IL-5, IL-10, TNF-α, and IFN-γ determinations were carried out by means of flow cytometry (Cytometric Bead Array, BD Biosciences). Determinations were made by the Unit of Investigation of the Hospital Reina Sofia (Cordoba). Samples were collected twice in the active and control groups: before initiating treatment (T0) and after finalizing follow-up (1 month after the end of pollen season, TF).

**Statistical analysis**

All statistical analyses were made with the SAS system, version 8.1. The association between variables was assessed with the Fisher exact test and intervals of confidence were calculated with a reliability of 95 % by means of the exact binomial method.

**RESULTS**

**Sample characteristics**

The characteristics of the patients are shown in Table II. The mean age of the patients was 26.2 ± 10.2 years and the mean duration of their allergy was 5.8 ± 4.7 years. There were 6 withdrawals for occupational or familial reasons, which were unrelated to the study, and 1 in compliance with the study protocol, due to the presentation of two consecutive systemic reactions. Nonetheless, this patient continued to receive immunotherapy and attained the maximum dose without further incidents.

**Treatment characteristics**

A total of 1,580 doses were administered, 1,199 in the initiation phase and 381 in the maintenance phase. The number of patients given immunotherapy, type of extract used, and number of controls are shown in Table II.
A total of 17 reactions were recorded in 15 patients. Three reactions were local and 14 were systemic. Systemic reactions occurred in 0.88% of the doses administered and in 12 patients (7.6% of all patients given immunotherapy). The reactions are described in table III. Of the 12 patients that had systemic reactions, 3 were treated with a 100% extract of grasses, 3 with a 100% Olea extract, and 6 with a mixture of both extracts; systemic reactions occurred in 5.7%, 17.7%, and 6.9%, respectively, of the patients treated with each extract. These differences were not statistically significant. By age groups, only 1 patient under the age of 14 years had a systemic reaction; all the other systemic reactions occurred in older patients. Again, the differences were not statistically significant.

Follow-up of symptoms and medication consumption

As shown in table IV, there was a significant decrease in the consumption of medications and frequency of symptoms between the active and control groups.

Determinations in vitro

The descriptive data of the variables studied at T0 and TF are summarized in table V. Analysis of the fit to a normal distribution using the Kolmogorov-Smirnov test is shown in table V. The mean and standard deviation for each group are presented in table V. The p-values for each variable are also shown in table V. The differences were statistically significant for all variables except for topical nasal steroids and topical bronchial steroids, which showed no statistically significant differences between the active and control groups.
and Shapiro-Wilk tests showed that the variables did not have a Gaussian distribution. Therefore, the evolution of these parameters in the two groups was studied by logarithmic transformation of the data. Results are given in table VI.

The immunological parameters changed in both groups over the course of the study period (T0-TF). The differences between the active and control groups at TF did not reach statistical significance, the most notable changes occurring in the IL-4 and IL-10 concentrations. All values are given in table VII.

**DISCUSSION**

The use of cluster schedules is becoming increasingly important, as indicated by the number of studies in which this type of initiation schedule has been used\(^9\). However, most of these studies were carried out at a single center or have small series, which makes it difficult to answer many of the questions inherent to the design of a schedule of this type: Is the schedule adaptable to different types of allergens? Does it have an adequate tolerance profile? Is the risk/benefit ratio favorable? Does it produce a savings in indirect costs to patients and health-care systems? Does raising the initiation doses with respect to those used in conventional schedules clinically benefit patients? Although it was not possible to answer all the questions that have been raised previously, the determination of certain investigators was fundamental for the development of the schedule proposed\(^10,11\). These studies provided the clinical base that facilitated the design and choice of the proposed schedule. The assumptions of this study derived from experience obtained previously in two multicenter studies carried out with mite and pollen extracts prepared by the same manufacturer\(^1,2\). In both cases, the same cluster schedule was used and a different tolerance profile was found with the two extracts. In the case of pollens, systemic reactions oc-
TOLERANCE AND SHORT-TERM EFFECT OF A CLUSTER SCHEDULE WITH POLLEN-EXTRACTS QUANTIFIED IN MASS-UNITS

Table VII

Differences at T0 and TF in Active and Control Group

<table>
<thead>
<tr>
<th>Differences (Wilcoxon)</th>
<th>Active Group</th>
<th>Control Group</th>
<th>Z</th>
<th>p value</th>
<th>Z</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-4</td>
<td>-6.11</td>
<td>0.0000</td>
<td>-3.30</td>
<td>0.0010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>-4.11</td>
<td>0.0000</td>
<td>-2.79</td>
<td>0.0052</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-10</td>
<td>-4.46</td>
<td>0.0000</td>
<td>-2.35</td>
<td>0.0188</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-2</td>
<td>-5.51</td>
<td>0.0000</td>
<td>-2.22</td>
<td>0.0299</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-γ</td>
<td>-4.82</td>
<td>0.0000</td>
<td>-2.26</td>
<td>0.0239</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td>-3.87</td>
<td>0.0001</td>
<td>-2.61</td>
<td>0.0092</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

REFERENCES

